Cargando…

The application and prospect of CDK4/6 inhibitors in malignant solid tumors

Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, which block the transition from the G1 to S phase of the cell cycle by interfering with Rb phosphorylation and E2F release, have shown potent antitumor activity and manageable toxicity in HR+/HER2− breast cancer patients. Some clinical trials involvin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Du, Qi, Guo, Xiang, Wang, Miao, Li, Yongfu, Sun, Xiaoyi, Li, Qin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195725/ https://www.ncbi.nlm.nih.gov/pubmed/32357912 http://dx.doi.org/10.1186/s13045-020-00880-8

Ejemplares similares

CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors
por: Schettini, Francesco, et al.
Publicado: (2018)

Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders
por: Wu, Xuewei, et al.
Publicado: (2021)

CDK6 Immunophenotype Implicates Potential Therapeutic Application of CDK4/6 Inhibitors in Urothelial Carcinoma
por: Sun, Ran, et al.
Publicado: (2022)

Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer
por: Hu, Ye, et al.
Publicado: (2021)

CDK4/6 inhibitors: a novel strategy for tumor radiosensitization
por: Yang, Yilan, et al.
Publicado: (2020)

Application of the CDK9 inhibitor FIT-039 for the treatment of KSHV-associated malignancy
por: Sakamoto, Tetsunori, et al.
Publicado: (2023)

Inducible deletion of CDK4 and CDK6 – deciphering CDK4/6 inhibitor effects in the hematopoietic system
por: Maurer, Barbara, et al.
Publicado: (2020)

CDK4/6 inhibitors: a brief overview and prospective research directions
por: Adon, Tenzin, et al.
Publicado: (2021)

Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer
por: Li, Zhen, et al.
Publicado: (2020)

INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors
por: Li, Qing, et al.
Publicado: (2022)

Application of Induced Pluripotent Stem Cells in Malignant Solid Tumors
por: He, Rong, et al.
Publicado: (2023)

CDK 4/6 inhibitors for the treatment of meningioma
por: Young, Jacob S., et al.
Publicado: (2022)

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
por: Al-Qasem, Abeer J., et al.
Publicado: (2022)

Editorial: Inhibitors of CDK family: New perspective and rationale for drug combination in preclinical models of solid tumors
por: Cavazzoni, Andrea, et al.
Publicado: (2023)

CDK4/6 inhibitor resistance: A bibliometric analysis
por: Pang, Jiayuecheng, et al.
Publicado: (2022)

Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
por: Yang, C, et al.
Publicado: (2017)

mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
por: Tian, Tian, et al.
Publicado: (2019)

CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells
por: Digiacomo, Graziana, et al.
Publicado: (2022)

Evaluation of the Effect of Food on the Pharmacokinetics of SHR6390, An Oral CDK4/6 Inhibitor, in Healthy Volunteers
por: Liu, Yan-ping, et al.
Publicado: (2022)

Molecular mechanism of G(1) arrest and cellular senescence induced by LEE011, a novel CDK4/CDK6 inhibitor, in leukemia cells
por: Tao, Yan-Fang, et al.
Publicado: (2017)

Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies and Solid Tumors
por: Federico, Mario, et al.
Publicado: (2011)

Acquired factor VIII inhibitor caused by solid tumor malignancy
por: de Bear, Olivia, et al.
Publicado: (2023)

CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors
por: Wang, Jiawan, et al.
Publicado: (2023)

A Phase I Dose-Escalation and Dose-Expansion Study of FCN-437c, a Novel CDK4/6 Inhibitor, in Patients with Advanced Solid Tumors
por: Patnaik, Amita, et al.
Publicado: (2022)

CDK4/6 inhibitor: from quiescence to senescence
por: Yoshida, Akihiro, et al.
Publicado: (2015)

CDK12 inactivation across solid tumors: an actionable genetic subtype
por: Marshall, Catherine H., et al.
Publicado: (2019)

Novel therapeutic strategy for melanoma based on albendazole and the CDK4/6 inhibitor palbociclib
por: Zhu, Lin, et al.
Publicado: (2022)

CDK4/6 inhibitor resistance mechanisms and treatment strategies (Review)
por: Huang, Jinyao, et al.
Publicado: (2022)

CDK6 and p16(INK4A) in lymphoid malignancies
por: Kollmann, Karoline, et al.
Publicado: (2013)

CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon restoration of RB function in malignant peripheral nerve sheath tumors
por: Wang, Jiawan, et al.
Publicado: (2023)

Carboxypeptidase vitellogenic like facilitates resistance to CDK4/6 inhibitors in breast cancer
por: Zhu, Xiang, et al.
Publicado: (2023)

The interplay of CDK4 and CDK6 in melanoma
por: Kollmann, Karoline, et al.
Publicado: (2019)

Expression of CDK6 in Stomach Cancer and the Effect of CDK4/6 Inhibitor PD-0332991 on the Function of Stomach Cancer Cells
por: Liu, Yu, et al.
Publicado: (2022)

Unraveling the genomic determinants of response to CDK4/6 inhibitors
por: Litchfield, Lacey M., et al.
Publicado: (2018)

The role of CDK4/6 inhibitors in early breast cancer
por: Gil-Gil, Miguel, et al.
Publicado: (2021)

Mechanisms and Implications of CDK4/6 Inhibitors for the Treatment of NSCLC
por: Zhang, Jinmeng, et al.
Publicado: (2021)

Unexpected toxicity of CDK4/6 inhibitor palbociclib and radiotherapy
por: van Aken, Evert S. M., et al.
Publicado: (2021)

CDK4/6 Inhibitors in Melanoma: A Comprehensive Review
por: Garutti, Mattia, et al.
Publicado: (2021)

CDK4/6 Inhibitors in Pancreatobiliary Cancers: Opportunities and Challenges
por: Arsenijevic, Tatjana, et al.
Publicado: (2023)

FOXM1, MEK, and CDK4/6: New Targets for Malignant Peripheral Nerve Sheath Tumor Therapy
por: Voigt, Ellen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_j72housf6f08lmn06ch9tk3icq